Fri, Mar 6, 2015, 5:14 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

RiceBran Technologies Message Board

  • sixth_8th sixth_8th Apr 1, 2013 7:16 PM Flag

    Positive nutracuetical comments from the 10 k

    "A 57-subject clinical trial conducted by Advanced Medical Research, with our funding, suggested that consumption of our RiSolubles nutritional supplements may lower blood glucose levels of type 1 and type 2
    diabetes mellitus patients and may be beneficial in reducing high blood cholesterol and high blood lipid levels. If warranted, we may develop products which address the use of SRB products as medical foods for, and to potentially make health benefit claims relating to, the effects of dietary rice bran on diabetes and cardiovascular disease."

    This next one looks good in conjunction with the protein just out
    "In December 2007, we formed Rice Science, LLC (RS), a Delaware limited liability company, with Herbal
    Science Singapore PTe. Ltd. (HS) to develop nutraceutical extracts and pharmaceutical chemistries from our SRB. HS utilizes sophisticated methodologies in the identification and isolation of specific biologically active compounds that have been tested for effectiveness against specific disease conditions. In March 2011, our partnership with HS ended with us acquiring the membership interest formerly owned by HS, leaving RS as our wholly owned subsidiary. We are hopeful that the research already performed will result in 29biologically active SRB extracts for use in the nutraceutical and functional food industry."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
RIBT
4.49+0.11(+2.51%)Mar 6 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.